iPrEx

Status:Completed
Phase:III
Principal Investigator(s):Robert M. Grant, MD, MPH
Objective:Determine whether daily oral TDF/FTC can reduce the risk of HIV infection in men who have sex men and transgender who also receive HIV counselling, condoms, and treatment for other STIs.Key result: 44% reduction in HIV infection rate among MSM across 11 sites in US, South America, Africa, and ThailandLast update August 9, 2022
Start Date
End Date
June 30, 2007
February 28, 2014
Enrollment:2,499
Age range: 18 Years ↔ any
Population:Gay and Bisexual Men Who Have Sex with Men